or Try an Advanced Search...

    Technical Analysis for AVTE - Aerovate Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 1.70 2.41% 0.04
    AVTE closed up 2.41 percent on Monday, July 1, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical AVTE trend table...
    Date Alert Name Type % Chg
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Narrow Range Bar Range Contraction 2.41%
    Inside Day Range Contraction 2.41%
    Wide Bands Range Expansion 2.41%
    Oversold Stochastic Weakness 2.41%
    Volume Surge Other 1.80%
    Narrow Range Bar Range Contraction 1.80%
    Wide Bands Range Expansion 1.80%
    Older End-of-Day Signals for AVTE ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 8 hours ago
    Rose Above Previous Day's High about 9 hours ago
    Up 3% about 9 hours ago
    Up 2% about 10 hours ago
    Up 1% about 10 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    AVTE Chart by TradingView
    Basic chart:

    Profile

    Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Clinical Medicine Chemical Compounds Hypertension Orphan Drug Pulmonary Arterial Hypertension Pulmonary Hypertension Imatinib Piperazines

    Is AVTE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 18 Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
    Jun 17 Aerovate Therapeutics Stock Dropped Over 90%. Here’s Why.
    Jun 17 Top Midday Decliners
    Jun 17 Why 90% Of Aerovate Therapeutics' Value Just Went Up In Smoke
    Jun 17 Why Is Small Cap-Heart Disease Focused Aerovate Therapeutics Stock Plummeting On Monday?
    Jun 17 Aerovate Therapeutics slides after its hypertension treatment fails to meet main goal
    Jun 17 Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
    Jun 11 Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
    Jun 11 Aerovate Therapeutics files for $350M mixed securities shelf
    Jun 6 Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation
    See more AVTE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 32.415
    52 Week Low 1.25
    Average Volume 1,237,103
    200-Day Moving Average 18.02
    50-Day Moving Average 16.51
    20-Day Moving Average 11.25
    10-Day Moving Average 1.55
    Average True Range 1.80
    RSI (14) 23.08
    ADX 38.46
    +DI 16.72
    -DI 52.38
    Chandelier Exit (Long, 3 ATRs) 19.88
    Chandelier Exit (Short, 3 ATRs) 6.65
    Upper Bollinger Bands 31.04
    Lower Bollinger Band -8.53
    Percent B (%b) 0.26
    BandWidth 351.53
    MACD Line -5.10
    MACD Signal Line -4.14
    MACD Histogram -0.9601
    Fundamentals Value
    Market Cap 47.04 Million
    Num Shares 27.7 Million
    EPS -2.74
    Price-to-Earnings (P/E) Ratio -0.62
    Price-to-Sales 0.00
    Price-to-Book 4.52
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.93
    Resistance 3 (R3) 1.92 1.85 1.89
    Resistance 2 (R2) 1.85 1.79 1.85 1.87
    Resistance 1 (R1) 1.77 1.75 1.81 1.78 1.86
    Pivot Point 1.70 1.70 1.72 1.70 1.70
    Support 1 (S1) 1.62 1.64 1.66 1.63 1.54
    Support 2 (S2) 1.55 1.60 1.55 1.53
    Support 3 (S3) 1.47 1.55 1.51
    Support 4 (S4) 1.48